134 related articles for article (PubMed ID: 14969416)
1. Refolding and purification of Apo2l/TRAIL produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli.
Shen YL; Xia XX; Zhang Y; Liu JW; Wei DZ; Yang SL
Biotechnol Lett; 2003 Dec; 25(24):2097-101. PubMed ID: 14969416
[TBL] [Abstract][Full Text] [Related]
2. High-level production of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in high-density cultivation of recombinant Escherichia coli using a combined feeding strategy.
Shen YL; Zhang Y; Sun AY; Xia XX; Wei DZ; Yang SL
Biotechnol Lett; 2004 Jun; 26(12):981-4. PubMed ID: 15269523
[TBL] [Abstract][Full Text] [Related]
3. Purification and characterization of recombinant sTRAIL expressed in Escherichia coli.
Xia XX; Shen YL; Wei DZ
Acta Biochim Biophys Sin (Shanghai); 2004 Feb; 36(2):118-22. PubMed ID: 14970907
[TBL] [Abstract][Full Text] [Related]
4. Refolding and structural characteristic of TRAIL/Apo2L inclusion bodies from different specific growth rates of recombinant Escherichia coli.
Kang H; Sun AY; Shen YL; Wei DZ
Biotechnol Prog; 2007; 23(1):286-92. PubMed ID: 17269700
[TBL] [Abstract][Full Text] [Related]
5. Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in Escherichia coli.
Hu ZM; Ma L; Zhou MQ; Gao JM; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1083-6. PubMed ID: 16939889
[TBL] [Abstract][Full Text] [Related]
6. Expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Lin Z; Lei H; Cao P
Protein Expr Purif; 2007 Feb; 51(2):276-82. PubMed ID: 17079165
[TBL] [Abstract][Full Text] [Related]
7. [High-cell density cultivation of recombinant Escherichia coli for production of TRAIL by using a 2-stage feeding strategy].
Zhang Y; Shen YL; Xia XX; Sun AY; Wei DZ; Zhou JS; Zhang GJ; Wang LH; Jiao BH
Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):408-13. PubMed ID: 15971615
[TBL] [Abstract][Full Text] [Related]
8. Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vitro & in vivo.
Guo BC; Xu YH
Acta Pharmacol Sin; 2001 Sep; 22(9):831-6. PubMed ID: 11749866
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification and crystallization of recombinant human TRAIL.
Cha SS; Shin HC; Choi KY; Oh BH
Acta Crystallogr D Biol Crystallogr; 1999 May; 55(Pt 5):1101-4. PubMed ID: 10216319
[TBL] [Abstract][Full Text] [Related]
10. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
11. High-level expression, purification, and in vitro refolding of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Wang D; Shi L
Appl Biochem Biotechnol; 2009 Apr; 157(1):1-9. PubMed ID: 19306078
[TBL] [Abstract][Full Text] [Related]
12. Optimization of culture on the overproduction of TRAIL in high-cell-density culture by recombinant Escherichia coli.
Luo Q; Shen YL; Wei DZ; Cao W
Appl Microbiol Biotechnol; 2006 Jun; 71(2):184-91. PubMed ID: 16215715
[TBL] [Abstract][Full Text] [Related]
13. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and refolding of thioredoxin/TRAIL fusion from inclusion bodies and further purification of TRAIL after cleavage by enteropeptidase.
Gasparian ME; Ostapchenko VG; Yagolovich AV; Tsygannik IN; Chernyak BV; Dolgikh DA; Kirpichnikov MP
Biotechnol Lett; 2007 Oct; 29(10):1567-73. PubMed ID: 17609857
[TBL] [Abstract][Full Text] [Related]
15. Improvement of expression level and bioactivity of soluble tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) by a novel zinc ion feeding strategy.
Sun AY; Shen YL; Yin JC; Zhang H; Tang YN; Wei DZ
Biotechnol Lett; 2006 Aug; 28(15):1215-9. PubMed ID: 16799759
[TBL] [Abstract][Full Text] [Related]
16. [Induction of apoptosis in various cancer cell lines by human soluble TRAIL expressed in Escherichia coli].
Zheng X; Guan X; Lin Z
Zhonghua Yi Xue Za Zhi; 2000 Mar; 80(3):190-2. PubMed ID: 11798756
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
18. GMP production and characterization of leucine zipper-tagged tumor necrosis factor-related apoptosis-inducing ligand (LZ-TRAIL) for phase I clinical trial.
Jiang J; Liu X; Deng L; Zhang P; Wang G; Wang S; Liu H; Su Y
Eur J Pharmacol; 2014 Oct; 740():722-32. PubMed ID: 24929054
[TBL] [Abstract][Full Text] [Related]
19. [A new Escherichia coli strain producing human tumor necrosis factor].
Surovtseva EV; Kuznetsova TV; Khomenkov VG; Domogatskiĭ SP; Shevelev AB
Bioorg Khim; 2005; 31(5):474-81. PubMed ID: 16245690
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/APO2L) and its receptors expression in human squamous cell carcinoma of the oral cavity.
Fukuda M; Hamao A; Tanaka A; Kitada M; Suzuki S; Kusama K; Sakashita H
Oncol Rep; 2003; 10(5):1113-9. PubMed ID: 12883666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
